Notice of Class Action Lawsuit for Gossamer Bio Securities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 36 minutes ago
0mins
Should l Buy GOSS?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to pay attention to the critical date of June 1, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants made overwhelmingly positive statements to investors while concealing material adverse facts regarding the study design of Gossamer's Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its extensive experience and success in the field, prompting investors to carefully select qualified legal counsel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.350
Low
10.00
Averages
12.33
High
15.00
Current: 0.350
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit for Gossamer Bio Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to pay attention to the critical date of June 1, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants made overwhelmingly positive statements to investors while concealing material adverse facts regarding the study design of Gossamer's Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its extensive experience and success in the field, prompting investors to carefully select qualified legal counsel.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply by June 1, 2026, to become Lead Plaintiff and protect their interests.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold, leading to a significant loss of market confidence.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by 80.13%, dropping $1.71 to close at $0.42, reflecting extreme pessimism among investors regarding the company's future prospects.
- Severe Legal Consequences: The lawsuit could result in substantial damages for Gossamer, as Pomerantz LLP, a prominent class action law firm, has historically secured multimillion-dollar settlements for victims, indicating the potential impact of this case.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. is facing a class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the announcement, Gossamer's stock price plummeted by 80%, reflecting extreme market pessimism regarding the company's future prospects, which could lead to further capital outflows and investor distrust.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly concerning disclosures about the PROSERA trial design, which may impact the company's reputation and future financing capabilities.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, indicating that the legal risks faced by the company could further deteriorate its financial condition and affect its listing status on Nasdaq.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between June 16, 2025, and February 20, 2026.
- False Statements Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to contact them before June 1, 2026, to participate in the recovery of losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and urges shareholders to take action before the class action is certified to ensure their rights are protected.
See More
Faruqi & Faruqi Investigates Claims Against Gossamer Bio for Investors
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Gossamer Bio, focusing on investors who purchased securities between June 16, 2025, and February 20, 2026, to assess potential claims, which may impact investors' legal options.
- Class Action Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against Gossamer, urging timely action to protect their rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to investor rights.
- Potential Impact Assessment: This investigation could lead to legal liabilities for Gossamer, and if investors succeed in their claims, it may negatively affect the company's financial standing and stock performance, prompting investors to closely monitor developments.
See More
Gossamer Bio Faces Securities Class Action Risk
- Stock Price Collapse: Gossamer Bio's shares plummeted over 80%, dropping $1.71 to $0.42 after revealing that its Phase 3 PROSERA study failed to meet its primary endpoint, which directly undermined investor confidence and triggered a class action lawsuit.
- Inadequate Risk Disclosures: Throughout the period from June 16, 2025, to February 20, 2026, Gossamer's announcements failed to adequately warn investors about specific risks related to patient selection in Latin American clinical trials, leading to a misjudgment of the company's prospects.
- Legal Allegations: The lawsuit alleges that Gossamer omitted critical information regarding significant deviations in patient characteristics at Latin American sites, which could lead to an outsized placebo response, highlighting severe deficiencies in the company's transparency.
- Investor Action Recommendations: Affected investors are advised to gather brokerage records and contact Levi & Korsinsky for a no-obligation evaluation to assess eligibility for claims before the lead plaintiff deadline of June 1, 2026.
See More
Notice of Class Action Lawsuit for Gossamer Bio Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to pay attention to the critical date of June 1, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants made overwhelmingly positive statements to investors while concealing material adverse facts regarding the study design of Gossamer's Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its extensive experience and success in the field, prompting investors to carefully select qualified legal counsel.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply by June 1, 2026, to become Lead Plaintiff and protect their interests.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold, leading to a significant loss of market confidence.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by 80.13%, dropping $1.71 to close at $0.42, reflecting extreme pessimism among investors regarding the company's future prospects.
- Severe Legal Consequences: The lawsuit could result in substantial damages for Gossamer, as Pomerantz LLP, a prominent class action law firm, has historically secured multimillion-dollar settlements for victims, indicating the potential impact of this case.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. is facing a class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the announcement, Gossamer's stock price plummeted by 80%, reflecting extreme market pessimism regarding the company's future prospects, which could lead to further capital outflows and investor distrust.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly concerning disclosures about the PROSERA trial design, which may impact the company's reputation and future financing capabilities.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, indicating that the legal risks faced by the company could further deteriorate its financial condition and affect its listing status on Nasdaq.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between June 16, 2025, and February 20, 2026.
- False Statements Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to contact them before June 1, 2026, to participate in the recovery of losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and urges shareholders to take action before the class action is certified to ensure their rights are protected.
See More
Faruqi & Faruqi Investigates Claims Against Gossamer Bio for Investors
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Gossamer Bio, focusing on investors who purchased securities between June 16, 2025, and February 20, 2026, to assess potential claims, which may impact investors' legal options.
- Class Action Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against Gossamer, urging timely action to protect their rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to investor rights.
- Potential Impact Assessment: This investigation could lead to legal liabilities for Gossamer, and if investors succeed in their claims, it may negatively affect the company's financial standing and stock performance, prompting investors to closely monitor developments.
See More
Gossamer Bio Faces Securities Class Action Risk
- Stock Price Collapse: Gossamer Bio's shares plummeted over 80%, dropping $1.71 to $0.42 after revealing that its Phase 3 PROSERA study failed to meet its primary endpoint, which directly undermined investor confidence and triggered a class action lawsuit.
- Inadequate Risk Disclosures: Throughout the period from June 16, 2025, to February 20, 2026, Gossamer's announcements failed to adequately warn investors about specific risks related to patient selection in Latin American clinical trials, leading to a misjudgment of the company's prospects.
- Legal Allegations: The lawsuit alleges that Gossamer omitted critical information regarding significant deviations in patient characteristics at Latin American sites, which could lead to an outsized placebo response, highlighting severe deficiencies in the company's transparency.
- Investor Action Recommendations: Affected investors are advised to gather brokerage records and contact Levi & Korsinsky for a no-obligation evaluation to assess eligibility for claims before the lead plaintiff deadline of June 1, 2026.
See More
